GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

其中，核心产品Biktarvy（比克替拉韦+恩曲他滨+丙酚替诺福韦）自2018年上市以来，销售额连年攀升，在2022年突破了100亿美元。2024年，该产品的销售额 ...